In the Press
June 22, 2020

Five Patent Issues That European Biosimilar Developers Should Consider Before Entering The US Market (European Pharmaceutical Review)

As patents on originator biologic medicines begin to expire, there are growing opportunities for biosimilars to enter the market at lower prices. Goodwin’s Intellectual Property lawyers Natasha Daughtrey and Grace Truong discuss key aspects of US patent law that European developers should consider before entering the American market. Read the European Pharmaceutical Review by-line here